Alex R Coffman1, Randa Tao2, Jessica N Cohan3, Lyen C Huang3, T Bartley Pickron3, Anna M Torgeson2, Shane Lloyd2. 1. Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA. 2. Department of Radiation Oncology, Huntsman Cancer Institute, Salt Lake City, Utah, USA. 3. Department of Surgery, Huntsman Cancer Institute, Salt Lake City, Utah, USA.
Abstract
BACKGROUND: Surgical resection is an integral component of the curative-intent treatment for most patients with non-metastatic rectal cancer. However, some patients refuse surgery for a number of reasons. Utilizing the National Cancer Database (NCDB), we investigated the sociodemographic and clinical factors associated with patients who were coded as having been offered but refused surgery, and the factors affecting overall survival (OS) in these patients. METHODS: Adult patients with adenocarcinoma of the rectum (excluding T1N0M0 and M1 disease) diagnosed from 2004 to 2015 were analyzed in this retrospective cohort study. Logistic regression was performed to identify factors associated with refusal of surgery. OS of patients refusing surgery was compared using Kaplan-Meier estimate, log-rank test, propensity score matching, and proportional hazards regression. RESULTS: A total of 55,704 patients were identified: 54,266 received definitive surgery (97.4%) and 1,438 refused (2.6%). Of patients refusing surgery, 135 (9.4%) were stage I, 709 (49.3%) were stage II, and 594 (41.3%) were stage III. Patients were more likely to refuse surgery as the study period progressed (P<0.01). Factors associated with refusal of surgery on multivariate analysis include: age ≥70 years, Black race, non-private insurance, and tumor size greater than 2 cm (all values P≤0.01). The 5-year OS was 61.6% for the surgery cohort and 35.7% for the refusal cohort. In the propensity matched groups, median survival was 84.2 months in patients who received definitive surgery compared to 43.7 months in patients who refused surgery. As an index for comparison, patients who refused surgery but received both radiotherapy and chemotherapy had a median survival of 48.5 months. Among patients that refused surgery, those that received radiotherapy alone, chemotherapy alone, or radiotherapy and chemotherapy (compared to no treatment) experienced a survival benefit (all values P≤0.01). CONCLUSIONS: In patients with non-metastatic adenocarcinoma of the rectum reported in the NCDB, age, race, and insurance status were associated with refusal of surgery. Refusal of surgery was more common in the later years of the study. Survival is poor in patients who refused surgical resection. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Surgical resection is an integral component of the curative-intent treatment for most patients with non-metastatic rectal cancer. However, some patients refuse surgery for a number of reasons. Utilizing the National Cancer Database (NCDB), we investigated the sociodemographic and clinical factors associated with patients who were coded as having been offered but refused surgery, and the factors affecting overall survival (OS) in these patients. METHODS: Adult patients with adenocarcinoma of the rectum (excluding T1N0M0 and M1 disease) diagnosed from 2004 to 2015 were analyzed in this retrospective cohort study. Logistic regression was performed to identify factors associated with refusal of surgery. OS of patients refusing surgery was compared using Kaplan-Meier estimate, log-rank test, propensity score matching, and proportional hazards regression. RESULTS: A total of 55,704 patients were identified: 54,266 received definitive surgery (97.4%) and 1,438 refused (2.6%). Of patients refusing surgery, 135 (9.4%) were stage I, 709 (49.3%) were stage II, and 594 (41.3%) were stage III. Patients were more likely to refuse surgery as the study period progressed (P<0.01). Factors associated with refusal of surgery on multivariate analysis include: age ≥70 years, Black race, non-private insurance, and tumor size greater than 2 cm (all values P≤0.01). The 5-year OS was 61.6% for the surgery cohort and 35.7% for the refusal cohort. In the propensity matched groups, median survival was 84.2 months in patients who received definitive surgery compared to 43.7 months in patients who refused surgery. As an index for comparison, patients who refused surgery but received both radiotherapy and chemotherapy had a median survival of 48.5 months. Among patients that refused surgery, those that received radiotherapy alone, chemotherapy alone, or radiotherapy and chemotherapy (compared to no treatment) experienced a survival benefit (all values P≤0.01). CONCLUSIONS: In patients with non-metastatic adenocarcinoma of the rectum reported in the NCDB, age, race, and insurance status were associated with refusal of surgery. Refusal of surgery was more common in the later years of the study. Survival is poor in patients who refused surgical resection. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
National Cancer Database (NCDB); Rectal cancer; refusal
Authors: Monique Maas; Regina G H Beets-Tan; Doenja M J Lambregts; Guido Lammering; Patty J Nelemans; Sanne M E Engelen; Ronald M van Dam; Rob L H Jansen; Meindert Sosef; Jeroen W A Leijtens; Karel W E Hulsewé; Jeroen Buijsen; Geerard L Beets Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Ane L Appelt; John Pløen; Henrik Harling; Frank S Jensen; Lars H Jensen; Jens C R Jørgensen; Jan Lindebjerg; Søren R Rafaelsen; Anders Jakobsen Journal: Lancet Oncol Date: 2015-07-05 Impact factor: 41.316
Authors: G D Steele; J E Herndon; R Bleday; A Russell; A Benson; M Hussain; A Burgess; J E Tepper; R J Mayer Journal: Ann Surg Oncol Date: 1999 Jul-Aug Impact factor: 5.344
Authors: Helena M Verkooijen; Gérald M Fioretta; Elisabetta Rapiti; Hervé Bonnefoi; Georges Vlastos; John Kurtz; Peter Schaefer; André-Pascal Sappino; Hyma Schubert; Christine Bouchardy Journal: Ann Surg Date: 2005-08 Impact factor: 12.969
Authors: Ayal A Aizer; Ming-Hui Chen; Arti Parekh; Toni K Choueiri; Karen E Hoffman; Simon P Kim; Neil E Martin; Jim C Hu; Quoc-Dien Trinh; Paul L Nguyen Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-03 Impact factor: 7.038
Authors: Andrew G Renehan; Lee Malcomson; Richard Emsley; Simon Gollins; Andrew Maw; Arthur Sun Myint; Paul S Rooney; Shabbir Susnerwala; Anthony Blower; Mark P Saunders; Malcolm S Wilson; Nigel Scott; Sarah T O'Dwyer Journal: Lancet Oncol Date: 2015-12-17 Impact factor: 41.316